| Medical and Health Sciences | Lifetime | 123 | US 70 | 99.99 |
| Biological Sciences | Lifetime | 113 | US 64 | 99.98 |
| Biological Sciences | 2021-2025 | 115 | US 20 | 99.90 |
| Medical and Health Sciences | 2021-2025 | 566 | US 196 | 99.88 |
| Genetics | Lifetime | 14 | US 6 | 99.96 |
| Clinical Neurology | Lifetime | 24 | US 9 | 99.92 |
| Pathology and Forensic Medicine | Lifetime | 64 | US 36 | 99.74 |
| Epidemiology | Lifetime | 236 | US 120 | 99.70 |
| Oncology | Lifetime | 180 | US 96 | 99.70 |
| Surgery | Lifetime | 403 | US 226 | 99.65 |
| Molecular Biology | Lifetime | 757 | US 460 | 99.61 |
| Endocrinology | Lifetime | 47 | US 29 | 99.19 |
| Cancer Research | Lifetime | 230 | US 120 | 98.66 |
| Infectious Diseases | Lifetime | 591 | US 307 | 97.58 |
| Rheumatology | Lifetime | 771 | US 355 | 96.04 |
| Reproductive Medicine | Lifetime | 531 | US 256 | 95.95 |
| Microbiology | Lifetime | 353 | US 161 | 93.44 |
| Molecular Medicine | Lifetime | 351 | US 91 | 89.83 |
| Veterinary Science and Animal Health | Lifetime | 865 | US 310 | 79.21 |
| Gastroenterology | Lifetime | 699 | US 266 | 72.03 |
| Genetics | 2021-2025 | 13 | US 5 | 99.80 |
| Oncology | 2021-2025 | 152 | US 66 | 98.85 |
| Clinical Neurology | 2021-2025 | 77 | US 22 | 98.30 |
| Molecular Biology | 2021-2025 | 514 | US 143 | 97.37 |
| Pathology and Forensic Medicine | 2021-2025 | 149 | US 59 | 96.25 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 499 | US 170 | 94.47 |
| Cancer Research | 2021-2025 | 177 | US 62 | 90.41 |
| Reproductive Medicine | 2021-2025 | 275 | US 91 | 84.44 |
| Meningioma and schwannoma management | Lifetime | 1 | US 1 | 99.98 |
| BRCA gene mutations in cancer | Lifetime | 1 | US 1 | 99.97 |
| Neurofibromatosis and Schwannoma Cases | Lifetime | 1 | US 1 | 99.99 |
| Genetic factors in colorectal cancer | Lifetime | 6 | US 4 | 99.93 |
| Hedgehog Signaling Pathway Studies | Lifetime | 2 | US 2 | 99.81 |
| Cancer Genomics and Diagnostics | Lifetime | 18 | US 13 | 99.93 |
| Genomic variations and chromosomal abnormalities | Lifetime | 8 | US 3 | 99.81 |
| Bone Tumor Diagnosis and Treatments | Lifetime | 10 | US 7 | 99.85 |
| Global Cancer Incidence and Screening | Lifetime | 12 | US 3 | 99.82 |
| Vascular Malformations Diagnosis and Treatment | Lifetime | 23 | US 19 | 99.69 |
| Escherichia coli research studies | Lifetime | 25 | US 16 | 99.60 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 66 | US 25 | 99.54 |
| Chromatin Remodeling and Cancer | Lifetime | 13 | US 7 | 99.40 |
| Soft tissue tumors and treatment | Lifetime | 5 | US 4 | 99.57 |
| Colorectal Cancer Screening and Detection | Lifetime | 93 | US 47 | 99.47 |
| Ovarian cancer diagnosis and treatment | Lifetime | 102 | US 59 | 99.43 |
| Cancer Risks and Factors | Lifetime | 53 | US 25 | 99.53 |
| Nutrition, Genetics, and Disease | Lifetime | 51 | US 22 | 99.15 |
| Cancer-related Molecular Pathways | Lifetime | 165 | US 101 | 99.28 |
| Genomics and Rare Diseases | Lifetime | 119 | US 72 | 98.69 |
| Multiple and Secondary Primary Cancers | Lifetime | 107 | US 48 | 98.55 |
| Cancer and Skin Lesions | Lifetime | 142 | US 76 | 98.59 |
| Tumors and Oncological Cases | Lifetime | 128 | US 84 | 98.52 |
| Antibiotic Resistance in Bacteria | Lifetime | 373 | US 117 | 98.79 |
| Neuroblastoma Research and Treatments | Lifetime | 232 | US 124 | 98.54 |
| Soft tissue tumor case studies | Lifetime | 89 | US 52 | 98.63 |
| DNA Repair Mechanisms | Lifetime | 362 | US 208 | 98.22 |
| Male Breast Health Studies | Lifetime | 13 | US 7 | 97.71 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 220 | US 107 | 98.15 |
| PARP inhibition in cancer therapy | Lifetime | 198 | US 101 | 97.26 |
| Sarcoma Diagnosis and Treatment | Lifetime | 648 | US 323 | 97.70 |
| Galectins and Cancer Biology | Lifetime | 291 | US 106 | 96.86 |
| Colorectal Cancer Treatments and Studies | Lifetime | 622 | US 263 | 98.20 |
| Bacterial Infections and Vaccines | Lifetime | 382 | US 157 | 97.10 |
| Eosinophilic Esophagitis | Lifetime | 521 | US 196 | 97.47 |
| Genetic Associations and Epidemiology | Lifetime | 574 | US 277 | 97.08 |
| Oral and Maxillofacial Pathology | Lifetime | 726 | US 252 | 96.73 |
| Lipid metabolism and disorders | Lifetime | 345 | US 135 | 96.27 |
| Vibrio bacteria research studies | Lifetime | 704 | US 258 | 95.52 |
| Digital Radiography and Breast Imaging | Lifetime | 329 | US 176 | 94.84 |
| Tactile and Sensory Interactions | Lifetime | 877 | US 277 | 94.60 |
| Family Support in Illness | Lifetime | 845 | US 393 | 93.52 |
| Diphtheria, Corynebacterium, and Tetanus | Lifetime | 253 | US 85 | 90.34 |
| Veterinary medicine and infectious diseases | Lifetime | 842 | US 214 | 88.32 |
| Digital Accessibility for Disabilities | Lifetime | 278 | US 125 | 85.86 |
| Travel-related health issues | Lifetime | 864 | US 227 | 79.34 |
| Intramuscular injections and effects | Lifetime | 469 | US 180 | 75.39 |
| BRCA gene mutations in cancer | 2021-2025 | 1 | US 1 | 99.84 |
| Neurofibromatosis and Schwannoma Cases | 2021-2025 | 1 | US 1 | 99.85 |
| Chromatin Remodeling and Cancer | 2021-2025 | 2 | US 1 | 99.15 |
| Global Cancer Incidence and Screening | 2021-2025 | 12 | US 6 | 99.36 |
| Cancer Genomics and Diagnostics | 2021-2025 | 42 | US 21 | 99.55 |
| Genetic factors in colorectal cancer | 2021-2025 | 18 | US 7 | 99.37 |
| Cancer Risks and Factors | 2021-2025 | 8 | US 3 | 99.19 |
| Genomic variations and chromosomal abnormalities | 2021-2025 | 13 | US 9 | 98.26 |
| Meningioma and schwannoma management | 2021-2025 | 21 | US 14 | 99.09 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 5 | US 2 | 97.97 |
| Genomics and Rare Diseases | 2021-2025 | 150 | US 61 | 95.75 |
| Nutrition, Genetics, and Disease | 2021-2025 | 65 | US 23 | 92.95 |
| Cancer-related Molecular Pathways | 2021-2025 | 114 | US 53 | 93.18 |
| Colorectal Cancer Screening and Detection | 2021-2025 | 346 | US 97 | 94.71 |
| Genetic Associations and Epidemiology | 2021-2025 | 279 | US 122 | 94.32 |
| Bone Tumor Diagnosis and Treatments | 2021-2025 | 115 | US 32 | 93.62 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 369 | US 110 | 94.72 |
| PARP inhibition in cancer therapy | 2021-2025 | 391 | US 156 | 89.02 |
| Prenatal Screening and Diagnostics | 2021-2025 | 738 | US 194 | 83.57 |
| Male Breast Health Studies | 2021-2025 | 28 | US 15 | 83.22 |
| DNA Repair Mechanisms | 2021-2025 | 813 | US 322 | 80.53 |
| Genetic and rare skin diseases. | 2021-2025 | 125 | US 26 | 75.30 |
| Cancer and Skin Lesions | 2021-2025 | 613 | US 187 | 71.31 |
| Estrogen and related hormone effects | 2021-2025 | 927 | US 273 | 70.86 |
| Ear and Head Tumors | 2021-2025 | 803 | US 229 | 65.55 |
| Digital Radiography and Breast Imaging | 2021-2025 | 606 | US 186 | 63.99 |